|
Date Submitted:
12/16/07
Hits: 18 Rating:  0/5 based on 0 votes
Glaxo gets US okay to buy heart drug maker Reliant
Description:
WASHINGTON, Dec 14 (Reuters) - U.S. antitrust authorities have cleared GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research) to buy privately held heart drug specialist Reliant Pharmaceuticals.
The Federal Trade Commission announced that antitrust authorities had found no reason to oppose the deal in a listing of completed merger reviews that it issues periodically. Glaxo, Europe's biggest drugmaker, said last month it planned to buy Reliant for $1.65 billion in cash. Reliant, which recorded net sales of $341 million in the nine months ending Sept. 30, has a portfolio of specialty drugs for heart disease, including U.S. rights to Lovaza, an omega-3 treatment for patients with very high levels of triglycerides. (Reporting by Diane Bartz; Editing by Brian Moss) Read the Complete Article Similar content: Glaxo grabs heart disease drug in $1.65bn deal, in Heart Disease Diabetes Drug Should Stay Despite Heart Risks, U.S. Advisers Say, in Arthritis Diabetes Drug AvandiaŽ Linked to Increased Risk of Heart Attacks, in Diabetes Hepatitis B Drug Triggers HIV Drug Resistance, in Hepatitis FACTBOX-Heart attacks often first symptom of heart disease, in Heart Disease |
